MiR-708-5p is inversely associated with EWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor

Roberto, Gabriela Molinari; Vieira, Gabriela Maciel; Delsin, Lara Elis Alberici; Silva, Marcela de Oliveira; Hakime, Rodrigo Guedes; Engel, Edgard Eduard; Scrideli, Carlos Alberto; Tone, Luíz Gonzaga; Brassesco, María Sol

doi:10.1016/j.cancergen.2018.11.003

Cited by 9 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…miR-708-5p is downregulated in ES cells and its overexpression is correlated with reduced proliferation of various tumours [49,50]. The overexpression of miR-708-5p suppresses the tumor invasiveness and migration, thanks to positively targeting Rho-GTPase Rho C effectors (ROCK1 and ROCK2) and Matrix Metallopeptidase 12 (MMP-12), respectively [51]. On the contrary, another oncomiR miR-181c acts as an ES tumor promotor by negatively targeting the Tumour Necrosis Factor Receptor Super Family Member 6 (TNFRSF6) in ES cells [52].…”

Section: Mirs In Es Development and Progressionmentioning

confidence: 99%

Oncomeric Profiles of microRNAs as New Therapeutic Targets for Treatment of Ewing’s Sarcoma: A Composite Review

Hassan,

Shahzadi,

Malik

et al. 2023

Genes

View full text Add to dashboard Cite

Ewing’s sarcoma is a rare type of cancer that forms in bones and soft tissues in the body, affecting mostly children and young adults. Current treatments for ES are limited to chemotherapy and/or radiation, followed by surgery. Recently, microRNAs have shown favourable results as latent diagnostic and prognostic biomarkers in various cancers. Furthermore, microRNAs have shown to be a good therapeutic agent due to their involvement in the dysregulation of various molecular pathways linked to tumour progression, invasion, angiogenesis, and metastasis. In this review, comprehensive data mining was employed to explore various microRNAs that might have therapeutic potential as target molecules in the treatment of ES.

show abstract

Section: Mirs In Es Development and Progressionmentioning

confidence: 99%

Oncomeric Profiles of microRNAs as New Therapeutic Targets for Treatment of Ewing’s Sarcoma: A Composite Review

Hassan,

Shahzadi,

Malik

et al. 2023

Genes

View full text Add to dashboard Cite

show abstract

“…Downregulation of miR-708-5p is also seen in another pediatric bone tumor, Ewing sarcoma, and inversely associated with the presence of the EWS/FLI1 translocation. However, in this tumor type no relations with any prognostic features such as HUVOS grade, event or survival were found [ 92 ]. Nonetheless, a previous study showed that miR-708 acts as a repressor of EYA3 and might be important for chemotherapy response in this childhood tumor [ 93 , 94 ].…”

Section: Mir-708 As a Hero: Its Role As Tumor Suppressormentioning

confidence: 99%

“…In this regard, miR-708 was firstly identified in serum from prostate cancer patients in 2014, and its inclusion in a “circulating miRNA” (c-miRNAs) panel has shown to allow the identification of disseminated versus localized tumors, evidencing its potential for staging this cancer type [ 92 ]. These so-called c-miRNAs have been repeatedly detected in many body fluids, including not only serum, but saliva, urine, sputum and even tears, which are easily collected [ 101 ] and show advantages over conventional invasive methods.…”

Section: Experimental Evidence For Mir-708 Interventionmentioning

confidence: 99%

The Double Face of miR-708: A Pan-Cancer Player with Dissociative Identity Disorder

Oliveira

Mathias

Oliveira

et al. 2022

Genes

Self Cite

View full text Add to dashboard Cite

Over the last decades, accumulating evidence has shown tumor-dependent profiles of miR-708, being either up- or downregulated, and thus, acting as a “Janus” regulator of oncogenic pathways. Herein, its functional duality was assessed through a thorough review of the literature and further validation in silico using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. In the literature, miR-708 was found with an oncogenic role in eight tumor types, while a suppressor tumor role was described in seven cancers. This double profile was also found in TCGA and GEO databases, with some tumor types having a high expression of miR-708 and others with low expression compared with non-tumor counterparts. The investigation of validated targets using miRBase, miRTarBase, and miRecords platforms, identified a total of 572 genes that appeared enriched for PI3K-Akt signaling, followed by cell cycle control, p53, Apellin and Hippo signaling, endocrine resistance, focal adhesion, and cell senescence regulations, which are all recognized contributors of tumoral phenotypes. Among these targets, a set of 15 genes shared by at least two platforms was identified, most of which have important roles in cancer cells that influence either tumor suppression or progression. In a clinical scenario, miR-708 has shown to be a good diagnostic and prognosis marker. However, its multitarget nature and opposing roles in diverse human tumors, aligned with insufficient experimental data and the lack of proper delivery strategies, hamper its potential as a sequence-directed therapeutic.

show abstract

“…With the in-depth research on the types and functions of miRNAs in recent years, their influence on the occurrence, development and prognosis of leukemia has become the focus of research by domestic and foreign researchers (3). Roberto et al (4) found that miR-708 is abnormally expressed in children with leukemia, but its relationship with the occurrence and development of leukemia has not yet been fully clarified. Previous studies believe that miR-708 can inhibit the migration and invasion of hepatocellular carcinoma cells.…”

Section: Introductionmentioning

confidence: 99%

MiR-708 regulates the biological behavior of childhood leukemia cells by binding to the 3'utr end of the target gene and reducing the level of the target gene

Li¹,

Zhang²,

Guan³

2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

This study was performed to analyze the biological behavior of childhood leukemia cells regulated by miR-708 by binding to the 3' UTR end of the target gene and reducing the level of the target gene. In this regard, human leukemia Jurkat cell lines were selected and divided into a control group, miR-708 overexpression group and miR-708 inhibition group. MTT assay was used to detect the cell proliferation inhibition rate, flow cytometry was used to detect the apoptosis rate and cell cycle change, the scratch test was used to detect the cell migration capacity, and Western Blot assay was used to detect the expression of CNTFR, apoptosis and JAK/STAT pathway related proteins. To verify the binding site of miR-708 and target gene CNTFR. The results showed that the cell proliferation inhibition rate, apoptosis rate, G1 phase ratio, Bax protein, and CNTFR protein in the miR-708 overexpression group were significantly lower than those in the control group at each time point, while the S phase ratio, Bcl-2 protein, cell migration ability, JAK3 and STAT3 protein were significantly higher than those in the control group (P<0.05). The results of the miR-708 inhibition group were contrary to those of the miR-708 overexpression group. The binding sites of miR-708 and CNTFR were predicted by TargetScan bioinformatics software. It was found that there were two binding sites of miR-708 and CNTFR, 394-400 bp and 497-503 bp respectively. In conclusion, miR-708 can reduce the expression of CNTFR by binding to the target gene CNTFR3' UTR, activate the JAK/STAT pathway to regulate apoptosis-related proteins, reduce apoptosis, and enhance the migration ability of leukemia cells.

show abstract

MiR-708-5p is inversely associated with EWS/FLI1 Ewing sarcoma but does not represent a prognostic predictor

Cited by 9 publications

References 36 publications

Oncomeric Profiles of microRNAs as New Therapeutic Targets for Treatment of Ewing’s Sarcoma: A Composite Review

Oncomeric Profiles of microRNAs as New Therapeutic Targets for Treatment of Ewing’s Sarcoma: A Composite Review

The Double Face of miR-708: A Pan-Cancer Player with Dissociative Identity Disorder

MiR-708 regulates the biological behavior of childhood leukemia cells by binding to the 3'utr end of the target gene and reducing the level of the target gene

Contact Info

Product

Resources

About